|Bid||133.00 x 1200|
|Ask||133.65 x 1000|
|Day's Range||130.64 - 138.60|
|52 Week Range||76.59 - 331.68|
|Beta (5Y Monthly)||1.59|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Biotech stocks are in a slump. Despite numerous wins in the high-profile areas of COVID-19 and cancer therapy, the industry has failed to excite investors this year -- as seen in the 12% year-to-date fall in the the bellwether SPDR S&P Biotech ETF. Risk-tolerant growth investors appear to be favoring other vehicles over biotech in 2021, such as the red-hot cryptocurrency Shiba Inu (CRYPTO: SHIB), electric-vehicle giant Tesla (NASDAQ: TSLA), and emerging social media plays such as Digital World Acquisition (NASDAQ: DWAC) and Phunware (NASDAQ: PHUN).
Good news for a rival's coronavirus vaccine compounds worries about the company's shot.
Gary Locke, former U.S. Commerce Secretary, talks vaccine distribution, intellectual property, and why cold storage and personnel are critical to fighting COVID-19 around the world.